Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives. (9th December 2015)

• Record Type: Journal Article
• Authors: Inno, Alessandro; Bogina, Giuseppe; Turazza, Monica; Bortesi, Laura; Duranti, Simona; Massocco, Alberto; Zamboni, Giuseppe; Carbognin, Giovanni; Alongi, Filippo; Salgarello, Matteo; Gori, Stefania
• Is Part Of: Oncologist. Volume 21:Number 1(2016)
• Page Start: 28
• Page End: 32
• Publication Date: 2015-12-09
• Subjects: Neuroendocrine breast carcinoma -- Neuroendocrine differentiation -- Carcinoid tumors -- Small-cell breast cancer -- Diagnosis -- Treatment; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2015-0309
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract: Neuroendocrine carcinoma of the breast is considered a rare entity, and for this reason there are no data from prospective clinical trials on its optimal management. Early stage tumors are usually treated with the same strategy used for the other types of invasive breast cancer. Anthracycline- and taxane-based regimens represent the most frequently administered chemotherapy in neoadjuvant and adjuvant setting, as well as for metastatic disease, although combinations of platinum compounds and etoposide have been widely used, in particular for small-cell histology and tumors with a high proliferation index. For metastatic disease, a multimodality therapeutic strategy can be considered on an individual basis, with chemotherapy, endocrine therapy, peptide receptor radionuclide therapy, radiation therapy, surgery, or a combination of the above. In the near future, a better knowledge of the biology of these tumors will hopefully provide new therapeutic targets for personalized treatment. In this review, we discuss the current evidence and the future perspectives on diagnosis and treatment of neuroendocrine carcinoma of the breast. Abstract : This review discusses the current evidence and the future perspectives on diagnosis and treatment of neuroendocrine carcinoma of the breast. A multimodality therapeutic strategy can be considered on an individual basis, with chemotherapy, endocrine therapy, peptide receptor radionuclide therapy, radiation therapy, surgery, or a combination. A better knowledge of the biology of these tumors will hopefully provide new therapeutic targets for personalized treatment.